Imatinib, a New Adjuvant Medical Treatment for Multifocal Villonodular Synovitis Associated to Noonan Syndrome: A Case Report and Literature Review

Romain Dalla-Torre1,2, Vincent Crenn3, Pierre Menu1,4,6, Bertrand Isidor7, Pascale Guillot2, Benoit Le Goff2, Loïc Geffroy8, Marc Dauty1,3,4,5 and Alban Fouasson-Chailloux1,3,4,6*

1 CHU Nantes, Service de Médicine Physique et de Réadaptation Locomotrice, University Hospital of Nantes, Nantes, France, 2 CHU Nantes, Service de Rhumatologie, University Hospital of Nantes, Nantes, France, 3 CHU de Nantes, Clinique Chirurgicale Orthopédique et Traumatologique, Hôtel-Dieu, Nantes, France, 4 CHU Nantes, Service de Médecine du Sport, University Hospital of Nantes, Nantes, France, 5 INSERM UMR U1229/RMeS, Regenerative Medicine and Skeleton – Nantes University, Nantes, France, 6 IRMS, Institut Régional de Médicine du Sport, Hôpital Saint Jacques, Nantes, France, 7 CHU Nantes, Service de Génétique Médicale, University Hospital of Nantes, Nantes, France, 8 Chirurgie Orthopédique, Santé Atlantique, Saint Herblain, France

Noonan syndrome (NS) is an autosomal dominant multisystem disorder caused by the dysregulation of the Rat Sarcoma/Mitogen-activated protein kinase (RAS/MAPK) pathway and characterized by short stature, heart defects, pectus excavatum, webbed neck, learning disabilities, cryptorchidism, and facial dysmorphism. Villonodular synovitis is a joint disorder most common in young adults characterized by an abnormal proliferation of the synovial membrane. Multifocal Villonodular synovitis is a rare disease whose recurrent nature can make its management particularly difficult. Currently, there is no systemic therapy recommended in diffuse and recurrent forms, especially because of the fear of long-term side effects in patients, who are usually young. Yet, tyrosine kinase inhibitors seem promising to reduce the effects of an aberrant colony stimulating factor-1 (CSF-1) production at the origin of the synovial nodule proliferation. We present here the case of a 21-year-old woman with NS associated to diffuse multifocal villonodular synovitis (DMVS). Our clinical case provides therapeutic experience in this very rare association. Indeed, in association with surgery, the patient improved considerably: she had complete daily life autonomy, knee joint amplitudes of 100° in flexion and 0° in extension and was able to walk for 10 min without any technical assistance. To our knowledge, this is the first case of a patient suffering from DMVS associated with a Noonan syndrome treated with Glivec® (oral administration at a dosage of 340 mg/m² in children, until disease regression) on a long-term basis.

Keywords: Noonan syndrome, multifocal villonodular synovitis, Imatinib, joints, case report
INTRODUCTION

Pigmented villonodular synovitis is a benign condition that can affect joints or tendon sheaths. It is characterized by the proliferation of the synovial tissue associated to a deposit of hemosiderin. It can be locally aggressive, leading to joint destruction due to repeated haemarthrosis (1). Chronic swelling and joint pain suggest the clinical diagnosis. MRI is the imaging modality of choice to explore the joint extension of this disease. Histopathology of synovial tissue is recommended in case of doubt to make the diagnosis. This is a rare disease whose recurrent nature can make therapeutic management particularly difficult. Synovectomy is the treatment of choice, under arthroscopy or open surgery depending on the case. However, the recurrence rate remains high (25–50%). Adjuvant techniques such as synoviorthesis and external radiotherapy have proven to be effective but do not prevent long-term recurrence. Currently there is no approved systemic therapy (2).

Noonan syndrome is an autosomal dominant multisystemic disorder subject to genetic heterogeneity. It is characterized by short stature, heart defects, pectus excavatum, webbed neck, cryptorchidism and facial dysmorphism, associated with learning difficulties (3, 4). This developmental disorder is linked to mutations in genes (PTPN11, SOS1, RAF1….) coding for various components of the Rat Sarcoma/Mitogen-activated protein kinase (RAS/MAPK) cell signaling pathway. This signaling cascade is also involved in many other inherited disorders such as cardio-facio-cutaneous syndrome (craniofacial dysmorphia, congenital heart disease, dermatoses, neurological manifestations, growth retardation, and intellectual disability), LEOPARD syndrome (ECG conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardations of growth, and deafness), Costello syndrome (growth retardation, short stature, developmental delay or intellectual deficit, joint laxity, loose skin and facial dysmorphic) and neurofibromatosis type 1 (café-au-lait spots, Lish nodules, lentigos on the armpits and inguinal region, and multiple neurofibromas) (5). It seems that joint manifestations are frequent, predominant in large joints (6). Despite potentially serious functional consequences, joint involvement has rarely been studied in the literature. Exceptionally, these syndromes may be associated with the development of single or multiple giant cell lesions such as pigmented villonodular synovitis (7). Many genes have been implicated but no geno-phenotype link has been proven so far. Deregulation of the RAS/MAPK cell signaling cascade is thought to be the basic molecular event pre-disposing to the formation of giant cell lesions without direct link to a specific genomic mutation.

We report a clinical case of a rare association, between a Noonan syndrome and a diffuse multifocal villonodular syndrome (DMVS), to share our therapeutic experience.

CASE PRESENTATION

A 21-year-old woman with Noonan syndrome due to a maternally inherited mutation (c.598 A4T, located in exon 5...
of the PTPN11 gene) had for several years been suffering from a DMVS, difficult to treat. The patient had characteristic polymorphism (depressed nasal wing, hypertelorism, sloping palpebral slits, posteriorly angled ears with thick helices), stature and weight retardation (Height: 151 cm; weight: 34 kg; BMI: 14.9 kg/m²).

In early childhood, the patient presented with a lesion of the right mandibular ramus with a diagnosis of giant cell granuloma. At the age of 7, characteristic MRI images—synovial hypertrophy, joint effusion, bone erosions, enhancement after gadolinium injection and especially hemosiderin deposits in the synovial masses appearing as a low signal area best seen...
on FFE sequence—strongly suggestive of the diagnosis of multifocal villonodular synovitis were identified in the knees and tibio-tarsal joints. This diagnosis was later confirmed by histopathological examination.

This DMVS was then managed by surgical synovectomies with a double approach on each of the four joints (Figure 1). Each surgical synovectomy was completed with Triamcinolone Hexacetonide synoviorthesis in the weeks following the surgical procedure. Rapidly, the first recurrences appeared in each of these joints, and lesions in the wrists appeared at the age of 11. The functional disability was relatively important with walking limited to short trips; the patient moving most of the time in a wheelchair. The evolution of the lesions, particularly in the right knee, led to the introduction of a basic treatment with Methotrexate. This treatment caused asthenia and was ineffective since it did not prevent the reappearance of knee pain associated with a new localization of the disease on the right elbow.

This failure of the initial management motivated a third line of treatment with a tyrosine kinase inhibitor of the Imatinib-type (Sandoz-France) (Glivec®), at a dose of 340 mg/m² from the age of 12. This new treatment was rapidly effective and well-tolerated. However, joint pain recur once 6 months after the treatment had been stopped, so it was restarted and prescribed for 3 years. The only notable side effects were intermittent asthenia and nausea, which were corrected by systematically taking an antiemetite before taking Glivec®. Unfortunately, the villonodular synovitis progressively recurred in the right knee despite the maximum dose of treatment prescribed. This recurrence was, at least partially attributable to a non-strict treatment compliance.

Finally, a surgical removal of the synovium allowed an improvement of the pain but required a joint mobilization under general anesthesia because of difficulties in recovering knee flexion. Currently, the patient has recovered complete autonomy, joint amplitudes are at 100° in flexion and 0° in extension, and walking can be performed for 10 min without technical aids. However, the radiographs show tricompartmental space loss, so that total knee prosthesis will probably be considered in the future (Figure 2).

**DISCUSSION**

The gold standard for the treatment of pigmented villonodular synovitis is surgical excision by a total synovectomy of the affected joint, using an open or an arthroscopic approach (8). However, the recurrence rate after surgery can be as high as 50%, leaving the possibility of using other treatment options (2). External beam radiation therapy at 30–50 Gy, used as monotherapy, has demonstrated local control of up to 95% while significantly decreasing DMVS recurrence when combined with surgical synovectomy (9).

In giant cell tumors, including villonodular synovitis, a neoplastic clone overexpressing colony stimulating factor-1 (CSF-1) has been described. A t (1;2) translocation that links the CSF-1 gene on chromosome 1p13 to the COL6A3 gene on chromosome 2q35 has been described and is thought to be responsible for the overproduction of CSF-1 by neoplastic cells (10, 11). Inhibition of CSF-1/CSF-1 receptor (CSF-1R) signaling is the target of new systemic therapies such as monoclonal antibodies and tyrosine kinase inhibitors. Among these agents, Imatinib, a tyrosine kinase inhibitor, has been studied in a multicenter retrospective cohort study of patients with recurrent diffuse villonodular synovitis (12). The treatment showed significant improvement (31% of overall response) but numerous adverse events were reported. Indeed, more than half of the patients had discontinued treatment due to drug toxicity.

The development of more specific tyrosine kinase inhibitors including Emactuzumab (SynOx Therapeutics- Ireland) and PLX3397 may have a promising future (2). Emactuzumab is a monoclonal antibody that binds directly to the CSF-1 receptor on the surface of macrophages to reduce or eliminate the effects of aberrant CSF-1 production. In a recent trial, 26 out of 28 patients with DMVS showed significant symptomatic improvement within 1–2 weeks of treatment with Emactuzumab (2). More recently in 2019, the CSF-1 receptor antagonist Pexidartinib (Daichi Sankyo - France) was approved by the FDA for its use in patients with DMVS who are unlikely to benefit from surgery. There are encouraging results, but they have to be qualified by the persistence of non-negligible side effects, particularly hepatic ones (13).

Initially, the association between Noonan’s syndrome and giant cell tumors was considered a separate syndrome (7, 14). It is now accepted that giant cell tumors belong to the spectrum of Noonan syndrome (10), as shown by our patient, who has a mutation transmitted by her mother who has a Noonan syndrome without DMVS.

A recent multicenter retrospective study evaluated the prevalence of joint pain in 71 patients with Noonan syndrome from 4 pediatric centers. The authors concluded that joint manifestations were common in Noonan syndrome, predominated in large joints, and that multiple villonodular synovitis were characteristic but rare (6).

In the literature, there are only few reported cases of association between Noonan syndrome and villonodular synovitis, and none of them reporting a management with Glivec® on long-term follow-up (Table 1).

Our clinical case provides therapeutic experience in this very rare association. There are data in the literature regarding the use of Glivec® in the treatment of giant cell tumors including uni and multifocal villonodular synovitis. One of the obstacles to the use of this long-term treatment in young patients is the lack of data on long-term follow-up. To our knowledge, this would be the first case of a patient suffering from DVMS associated with a Noonan syndrome treated with Glivec® on such a long term basis. Few cases of villonodular synovitis treated with Glivec® have been reported (18–20). Case series show a symptomatic efficacy of around 30% and stabilize the lesions in 60–65% of the cases, whereas discontinuation of treatment due to side effects is encountered in ~12–20% of the cases (Table 2).

In case of failure or non-tolerance, surgery makes it possible to reduce the tumor inoculum as much as possible in order to recover indolence and joint mobility thanks to
rehabilitation care. Thus, the handicap of movement is reduced when a joint such as the knee or the ankle is treated. It is hoped to improve the quality of life while delaying the destruction of the joint, which will eventually require the replacement of the joint with a prostheses. Indeed, DMVS is a potentially aggressive benign tumor which, as in our patient, is difficult to control. A multidisciplinary approach with surgeons, rheumatologists, radiologists, oncologists and rehabilitation physicians is essential.

CONCLUSION

Multifocal villonodular synovitis is rarely associated to Noonan syndrome due to a link with a deregulation of the RAS/MAPK cell signaling cascade responsible for giant cell tumor formation. Treatment is multidisciplinary with priority given to surgical synovectomy. Adjuvant treatments exist for diffuse recurrent forms such as external radiotherapy or synoviorthesis. No systemic therapy is currently recommended, especially because of the fear of long-term side effects in patients who are usually young, but, if the side effects are tolerated, tyrosine kinase inhibitors seem promising to reduce the effects of aberrant CSF-1 production at the origin of synovial nodule formation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Written informed consent was obtained from the patient for publication of this case report.

AUTHOR CONTRIBUTIONS

RD-T, MD, and AF-C: conceptualization, methodology, and writing—original draft preparation. MD and PM: formal analysis. LG, VC, PG, BL, and BI: surgery and patient management. PM, LG, VC, PG, BL, and BI: writing—review and editing. All authors have read and agreed to the submitted version of the manuscript.

REFERENCES

1. Bhimani MA, Wenz JF, Frassica FJ. Pigmented villonodular synovitis: keys to early diagnosis. Clin Orthop Relat Res. (2001) 386:197–202. doi: 10.1097/00003086-200105000-00025
2. Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol. (2016) 17:10. doi: 10.1007/s11864-015-0385-x
3. Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. (1968) 116:373–80. doi: 10.1001/archpedi.1968.02100020377005
4. Allanson JE. Noonan syndrome. J Med Genet. (1987) 24:9–13. doi: 10.1136/jmg.24.1.9
5. Neumann TE, Allanson J, Kavamura I, Kerr B, Neri G, Noonan J, et al. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet. (2009) 17:420–5. doi: 10.1038/ejhg.2008.188
6. Le Quellec A, Edouard T, Audebert-Bellanger S, Pouzet A, Bourdet K, Colson C, et al. Joint involvement in Noonan syndrome. A retrospective paediatric descriptive study. Joint Bone Spine. (2021) 89:105270. doi: 10.1016/j.jbspin.2021.105270
7. Cohen MM, Gorlin RJ. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet. (1991) 40:159–66. doi: 10.1002/ajmg.a.32538
8. Chang JS, Higgins JP, Kosy JD, Theodoropoulos J. Systematic arthroscopic treatment of diffuse pigmented villonodular synovitis in the knee. Arthrosc Tech. (2017) 6:e1547–51. doi: 10.1016/j.ArthroscTech.2017.06.029
9. Mollon B, Lee A, Busse JW, Griffin AM, Ferguson PC, Wunder JS, Theodoropoulos J. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. (2015) 97-B:550–7. doi: 10.1302/0301-620X.97B4.34907
10. Carapito R, Paul N, Untrau M, Ott L, Corradini N, Poignant S, et al. A new mutation in the C-SH2 domain of PTEN11 causes Noonan syndrome with multiple giant cell lesions. J Hum Genet. (2014) 59:57–9. doi: 10.1038/jhg.2013.118
11. Mascheroni E, Digilio MC, Cortis E, Devito R, Sarkozy A, Capolin R, et al. Pigmented villonodular synovitis in a patient with Noonan syndrome and SOS1 gene mutation. Am J Med Genet A. (2008) 146A:2966–7. doi: 10.1002/ajmg.a.32538
12. Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Sci Rep. (2019) 9:14551. doi: 10.1038/s41598-019-51211-y
13. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay J-Y, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. (2019) 394:478–87. doi: 10.1016/S0140-6736(19)30764-0
14. Benetache C, Cavé H, Moncla A, Dorison N, Munnich A, Verloes A, et al. SOS1 and PTEN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet. (2009) 17:1216–21. doi: 10.1038/ejhg.2009.44
15. Vavrik J, Jarosová K, Popelka S. Polyarticular form of pigmented villonodular synovitis. Radiation and surgical therapy: long term follow-up. Acta Chir Orthop Traumatol Cech. (2008) 75:392–5.
16. Meyers AB, Awomolo AO, Szabo S. Multifocal tenosynovial giant cell tumors in a child with Noonan syndrome. Pediatr Radiol. (2017) 47:361–5. doi: 10.1007/s00247-016-3743-3
17. Mori O, Bonnet N, Lysy P, Loucheur N, Gayitto R, Docquier PL. Multifocal pigmented villonodular synovitis in the noonan syndrome. Case Rep Orthop. (2018) 2018:8698052. doi: 10.1155/2018/8698052
18. Blay J-Y, El Sayadi H, Thiessé P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. (2008) 19:821–2. doi: 10.1093/annonc/mdn033
19. Snoots WM, Watkins D, Dockery D, Mennel R, Cheek BS. Pigmented villonodular synovitis responsive to imatinib therapy. Proc (Bayl Univ Med Cent). (2011) 24:134–8. doi: 10.1080/08998280.2011.1192870
20. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, et al. Response to imatinib in villonodular pigmented synovitis (PVNS/TGCT). Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. (2008) 19:821–2. doi: 10.1093/annonc/mdn033
21. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or
metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. (2012) 118:1649–55. doi: 10.1002/cncr.26409

22. Mastboom MJL, Lips W, van Langevelde K, Mifsud M, Ng C, McCarthy CL, et al. J. The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT. Surg Oncol. (2020) 35:261–7. doi: 10.1016/j.suronc.2020.08.030

23. Brahmi M, Cassier P, Dufresne A, Chabaud S, Karanian M, Meurgey A, et al. Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). PLoS ONE. (2020) 15:e0233046. doi: 10.1371/journal.pone.0233046

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Dalla-Torre, Crenn, Menu, Isidor, Guillot, Le Goff, Geffroy, Dauty and Fouasson-Chailloux. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.